Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma.

Despite these inherent NCDB-associated limitations, our study is significant as we demonstrate in a large-population SN-ENKTL patient cohort that varying clinical and demographic/socioeconomic factors can significantly impact treatment receipt and chemoradiotherapy significantly improves OS. To the Editor, Sinonasal extranodal natural killer/T-cell lymphoma (SN-ENKTL) is a rare and aggressive subtype of non-Hodgkin's lymphoma [[1]] which is characterized by progressive necrotizing local destruction into bone, soft tissue, and cartilaginous structures [[2]]. There were no significant demographic/socioeconomic differences between early- and late-stage patients, however late-stage patients were associated with receiving chemotherapy (42.2%), while early-stage patients were associated with receiving chemoradiotherapy (45.8%) as treatment ( I p i < 0.001). Recently, autologous or allogenic stem cell and bone marrow transplantations have been proposed as a treatment option for SN-ENKTL patients to prolong disease prognosis as either initial therapy or following chemotherapy. [Extracted from the article]